|
|
Article: Par Pharmaceutical Receives Final Approval to Market Generic Questran(R) Powder and Questran(R) Light Powder for Oral Suspension.
- Article from:
- PR Newswire
- Article date:
- August 29, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SPRING VALLEY, N.Y., Aug. 29 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Applications for cholestyramine for oral suspension, 4g resin/9g powder and cholestyramine for oral suspension, (light), 4g resin/5g powder. Cholestyramine is the generic version of Bristol-Myers Squibb Company's Questran(R) Powder and Questran(R) Light Powder for Oral Suspension, and is used for the treatment of primary hypercholesterolemia. U.S. sales of cholestyramine products are approximately $50 million, according to IMS health. Cholestyramine for oral ...